Immunic Strengthens Biotech Presence at Upcoming Investor Conferences This March

Immunic, Inc. Expands Engagement at Key Healthcare Conferences

Immunic, Inc., a late-stage biotechnology company, is actively reinforcing its presence within the biotech community through its participation in two major investor conferences this March. The company, which focuses on developing innovative oral therapies for neurologic and gastrointestinal diseases, sees these upcoming events as crucial opportunities to engage with investors and stakeholders. At the Leerink Partners Global Healthcare Conference from March 8-11, Immunic's leadership team, including CEO Daniel Vitt, COO Jason Tardio, and VP of Investor Relations Jessica Breu, will partake in a fireside chat on March 11 at 10:40 am ET. This discussion will be available for streaming on Immunic's website, further emphasizing the company’s commitment to transparency and investor engagement.

Following the Leerink conference, Immunic will continue its outreach at the Stifel 2026 Virtual CNS Forum on March 17-18. Here, they will host another fireside chat on March 18 at 4:00 pm ET, offering insights into their development pipeline and the broader implications of their research. Both events present strategic platforms for Immunic to communicate progress on its lead program, vidofludimus calcium (IMU-838), which is currently undergoing phase 3 clinical trials aimed at treating relapsing multiple sclerosis. The eagerly anticipated top-line data from this trial is expected by the end of 2026 and could signal a significant advancement in multiple sclerosis treatment options.

In addition to IMU-838, Immunic is also innovating within the gastrointestinal space with its drug IMU-856, designed to activate Sirtuin 6 (SIRT6) to combat conditions such as celiac disease and inflammatory bowel disease. The dual focus on neurologic and gastrointestinal disorders reflects Immunic's mission to address unmet medical needs. Furthermore, the company is exploring next-generation molecules in preclinical testing that leverage its Nurr1 platform. As Immunic positions itself more firmly within the biotech landscape, these upcoming conferences serve not only as platforms for dialogue but also as key indicators of the company’s strategic direction for 2026 and beyond.

In summary, Immunic's involvement in March's investor conferences illustrates its dedication to fostering investor relations and promoting its pioneering research programs. As the company navigates crucial clinical milestones, it aims to share its vision for advancements in treatment options for complex and often debilitating diseases. This focus positions Immunic as a significant player in the biopharmaceutical arena, committed to innovative solutions in both neurology and gastrointestinal conditions. Further details can be accessed through Immunic's official website, www.imux.com.